Independent Advisor Alliance Buys 1,745 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Independent Advisor Alliance increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 29.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,719 shares of the company’s stock after acquiring an additional 1,745 shares during the quarter. Independent Advisor Alliance’s holdings in CRISPR Therapeutics were worth $363,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. SevenBridge Financial Group LLC raised its holdings in CRISPR Therapeutics by 7.5% in the third quarter. SevenBridge Financial Group LLC now owns 6,076 shares of the company’s stock worth $285,000 after purchasing an additional 425 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of CRISPR Therapeutics by 0.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 724,241 shares of the company’s stock valued at $34,025,000 after buying an additional 6,635 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth $43,000. Advisors Asset Management Inc. lifted its holdings in CRISPR Therapeutics by 3.7% during the third quarter. Advisors Asset Management Inc. now owns 9,669 shares of the company’s stock worth $454,000 after acquiring an additional 342 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its stake in CRISPR Therapeutics by 1.0% in the third quarter. Thrivent Financial for Lutherans now owns 47,696 shares of the company’s stock valued at $2,241,000 after acquiring an additional 473 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Up 3.1 %

CRSP stock opened at $50.84 on Friday. The business’s 50 day simple moving average is $48.07 and its 200 day simple moving average is $51.68. CRISPR Therapeutics AG has a 1-year low of $43.42 and a 1-year high of $91.10. The firm has a market capitalization of $4.34 billion, a PE ratio of -17.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the prior year, the firm earned ($1.41) earnings per share. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. The trade was a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 35,382 shares of company stock worth $1,917,679 over the last three months. Insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Chardan Capital dropped their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Truist Financial lowered their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Barclays cut their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Finally, Rodman & Renshaw initiated coverage on CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.